Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 3

1(12.5%)

Phase 2

1(12.5%)

8Total

Phase 1(6)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02240238Phase 1Completed

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

Role: lead

NCT02817113Phase 1Terminated

Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

Role: collaborator

NCT03771820Phase 2Unknown

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Role: lead

NCT02043288Phase 3Completed

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Role: collaborator

NCT03168061Phase 1Unknown

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

Role: lead

NCT03109158Phase 1Completed

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Role: lead

NCT03168035Phase 1Completed

Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

Role: lead

NCT00910741Phase 1Completed

NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia

Role: lead

All 8 trials loaded